Generic Biologics On FDA Fast Track?: “Follow-On” Process Under Debate
Executive Summary
Data requirements for generic biologics approved under the 505(b)(2) process will be taken up by FDA over the next six months, Center for Drug Evaluation & Research Director Janet Woodcock, MD, said
You may also be interested in...
FDA Generic Biologics “Structure” To Come Soon; Policy Debate In 2005
FDA hopes to be in a position to kick off a legislative and policy debate on the feasibility of "follow-on" biologics by the beginning of 2005
FDA Generic Biologics “Structure” To Come Soon; Policy Debate In 2005
FDA hopes to be in a position to kick off a legislative and policy debate on the feasibility of "follow-on" biologics by the beginning of 2005
Generic Biologics: 505(b)(2) Route Still Open, But Scientific Issues Unresolved
FDA is declining to rule out the possibility that the Sec. 505(b)(2) process could be used to allow expedited approval of follow-on biologic projects